Implications of the colonic deposition of free hemoglobin-α chain: A previously unknown tissue by-product in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 9, 2014, Pages 1530-1547

  Myers, Jeremy N ^a   Schäffer, Michael W ^a   Korolkova, Olga Y ^a   Williams, Amanda D ^a   Gangula, Pandu R ^a   M'Koma, Amosy E ^a,b,c  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Carcinogenesis; CAT; DNA damage; GPx; Hb; Hb(n); Hemin; IBD; Nrf2; Risks; ROS; SOD

Indexed keywords

BETA ACTIN; HEMIN; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; NFE2L2 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE;

ADULT; APOPTOSIS; ARTICLE; COLON CANCER; COLORECTAL CANCER; COMET ASSAY; CONTROLLED STUDY; CROHN DISEASE; DENSITOMETRY; DIVERTICULITIS; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIDDLE AGED; PRIORITY JOURNAL; TISSUE HOMOGENATE; ULCERATIVE COLITIS; WESTERN BLOTTING; ADOLESCENT; AGED; CELL SURVIVAL; COLON; COLON TUMOR; COMPLICATION; FOLLOW UP; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-GLOBINS; ANTIOXIDANTS; BLOTTING, WESTERN; CELL SURVIVAL; COLITIS, ULCERATIVE; COLON; COLONIC NEOPLASMS; COMET ASSAY; CROHN DISEASE; DNA DAMAGE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROGNOSIS; REACTIVE OXYGEN SPECIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 84925843601     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000144     Document Type: Article

References (138)

1. M'Koma AE, Seeley EH, Washington MK, et al. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm Bowel Dis. 2011;17: 875-883.
2. Seeley EH, Washington MK, Caprioli RM, et al. Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis. Proteomics Clin Appl. 2013;7:541-549.
3. Roessner A, Kuester D, Malfertheiner P, et al. stress in ulcerative colitisassociated carcinogenesis. Pathol Res Pract. 2008;204:511-524.
4. Lih-Brody L, Powell SR, Collier KP, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci. 1996;41:2078-2086.
5. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet. 1994;344:859-861.
6. Halliwell B, Gutteridge JM. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys. 1986;246:501-514.
7. Sturniolo GC, Tuccari G, D'Inca R. Mucosal iron concentration and immunohistochemical evidence of iron-binding proteins in longstanding ulcerative colitis. Intal J Gastroenterol. 1993;25:A68.
8. McFaul SJ, Bowman PD, Villa VM. Hemoglobin stimulates the release of proinflammatory cytokines from leukocytes in whole blood. J Lab Clin Med. 2000;135:263-269.
9. McFaul SJ, Bowman PD, Villa VM, et al. Hemoglobin stimulates mononuclear leukocytes to release interleukin-8 and tumor necrosis factor alpha. Blood. 1994;84:3175-3181.
10. Connelly TM, Koltun WA. The cancer "Fear" in IBD patients: is it still REAL? J Gastrointest Surg. 2014;18:213-218.
11. Averboukh F, Ziv Y, Kariv Y, et al. Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn's and ulcerative colitis. Colorectal Dis. 2011;13:1230-1235.
12. Um JW, M'Koma AE. Pouch-related dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Tech Coloproctol. 2011;15:7-16.
13. M'Koma AE, Moses HL, Adunyah SE. Inflammatory bowel diseaseassociated colorectal cancer: proctocolectomy and mucosectomy does not necessarily eliminate pouch related cancer incidences. Int J Colorectal Dis. 2011;26:533-552.
14. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228-1233.
15. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet. 1990;336: 357-359.
16. Mantovani A, Romero P, Palucka AK, et al. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 2008;371: 771-783.
17. Lorusso G, Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008;130: 1091-1103.
18. M'Koma AE, Seeley EH, Wise PE, et al. Proteomic analysis of colonic submucosa differentiates Crohn's and ulcerative colitis. Gastroenterology. 2009;136:A349.
19. M'Koma AE, Seeley EH, Wise PE, et al. Proteomic patterns of colonic submucosa discriminates inflammatory colitides. Dis Colon Rectum Abstractor. 2008-2010.
20. M'Koma A, Wise PE, Seeley EH, et al. Human alpha defensins are differentially expressed between the inflammatory colitides. Gastroenterology. 2010;138:S525.
21. M'Koma A, Wise PE, Schwartz DA, et al. Gene Expression of Colonic Submucosa Differs Between the Inflammatory Colitides. Annual Congress-The American Society of Colon and Rectal Surgeons, Minneapolis, MN, 2010.
22. Krzystek-Korpacka M, Neubauer K, Berdowska I, et al. Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: impact of anemia and treatment. Inflamm Bowel Dis. 2010;16:1467-1475.
23. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Aliment Pharmacol Ther. 2002;16:1997-2015.
24. D'Odorico A, Bortolan S, Cardin R, et al. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol. 2001;36:1289-1294.
25. Krzystek-Korpacka M, Neubauer K, Berdowska I, et al. Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis. 2008;14:794-802.
26. Boehm D, Krzystek-Korpacka M, Neubauer K, et al. Paraoxonase-1 status in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2009;15:93-99.
27. Koutroubakis IE, Malliaraki N, Dimoulios PD, et al. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1433-1437.
28. Puri KS, Suresh KR, Gogtay NJ, et al. Declaration of helsinki, 2008: implications for stakeholders in research. J Postgrad Med. 2009;55: 131-134.
29. Schey KL, Anderson DM, Rose KL. Spatially-directed protein identification from tissue sections by top-down LC-MS/MS with electron transfer dissociation. Anal Chem. 2013;85:6767-6774.
30. Maamer-Azzabi A, Ndozangue-Touriguine O, Breard J. Metastatic SW620 colon cancer cells are primed for death when detached and can be sensitized to anoikis by the BH3-mimetic ABT-737. Cell Death Dis. 2013;4:e801.
31. Gangula PR, Chinnathambi V, Hale AB, et al. Impairment of nitrergic system and delayed gastric emptying in low density lipoprotein receptor deficient female mice. Neurogastroenterol Motil. 2011;23: 773-e335.
32. Ravella K, Yang H, Gangula PR. Impairment of gastric nitrergic and NRF2 system in apolipoprotein E knockout mice. Dig Dis Sci. 2012;57: 1504-1509.
33. van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237-245.
34. Megalopoulou TM, Koutroumbas K, Pouliakis A, et al. The potential of feature selection by statistical techniques and the use of statistical classifiers in the discrimination of benign from malignant gastric lesions. Oncol Rep. 2006;15:1033-1036.
35. Webb A. Statistical Pattern Recognition. Chichester, United Kingdom: John Wiley & Sons; 2000.
36. Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr Rev. 2012;70:257-265.
37. Mason PA, Cox LS. The role of DNA exonucleases in protecting genome stability and their impact on ageing. Age (Dordr). 2012;34: 1317-1340.
38. Pickering AM, Koop AL, Teoh CY, et al. The immunoproteasome, the 20S proteasome and the PA28alphabeta proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem J. 2010;432: 585-594.
39. Dasuri K, Zhang L, Ebenezer P, et al. Proteasome alterations during adipose differentiation and aging: links to impaired adipocyte differentiation and development of oxidative stress. Free Radic Biol Med. 2011; 51:1727-1735.
40. Rhodes JM. Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Lancet. 1996;347:40-44.
41. Rubin DT, Parekh N. Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. Curr Treat Options Gastroenterol. 2006;9:211-220.
42. Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol. 1996;13:339-357.
43. Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am. 2006;35: 517-531.
44. Vleggaar FP, Lutgens MW, Oldenburg B, et al. British and American screening guidelines inadequate for prevention of colorectal carcinoma in patients with inflammatory bowel disease [in Dutch]. Ned Tijdschr Geneeskd. 2007;151:2787-2791.
45. Svrcek M, Cosnes J, Beaugerie L, et al. Colorectal neoplasia in Crohn's colitis: a retrospective comparative study with ulcerative colitis. Histopathology. 2007;50:574-583.
46. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459.
47. Hardy RG, Meltzer SJ, Jankowski JA. ABC of colorectal cancer. Molecular basis for risk factors. BMJ. 2000;321:886-889.
48. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561-1567.
49. Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2:1088-1095.
50. Surova O, Zhivotovsky B. Various modes of cell death induced by DNA damage. Oncogene. 2013;32:3789-3797.
51. Asaithamby A, Chen DJ. Mechanism of cluster DNA damage repair in response to high-atomic number and energy particles radiation. Mutat Res. 2011;711:87-99.
52. Sanford KK, Price FM, Brodeur C, et al. Deficient DNA repair in chronic ulcerative colitis. Cancer Detect Prev. 1997;21:540-545.
53. Meyer JN, Bess AS. Involvement of autophagy and mitochondrial dynamics in determining the fate and effects of irreparable mitochondrial DNA damage. Autophagy. 2012;8:1822-1823.
54. Shrotriya S, Deep G, Gu M, et al. Generation of reactive oxygen species by grape seed extract causes irreparable DNA damage leading to G2/M arrest and apoptosis selectively in head and neck squamous cell carcinoma cells. Carcinogenesis. 2012;33:848-858.
55. Weinberger M, Feng L, Paul A, et al. DNA replication stress is a determinant of chronological lifespan in budding yeast. PLoS One. 2007;2:e748.
56. Dykens JA, Baginski TJ. Urinary 8-hydroxydeoxyguanosine excretion as a non-invasive marker of neutrophil activation in animal models of inflammatory bowel disease. Scand J Gastroenterol. 1998;33:628-636.
57. Kelly GL, Strasser A. The essential role of evasion from cell death in cancer. Adv Cancer Res. 2011;111:39-96.
58. Tagawa Y, Sanders JD, Uchida I, et al. Genetic and functional analysis of Haemophilus somnus high molecular weight-immunoglobulin binding proteins. Microb Pathog. 2005;39:159-170.
59. Cory JG. Ribonucleotide reductase as a chemotherapeutic target. Adv Enzyme Regul. 1988;27:437-455.
60. Adams CW, Fornwald JA, Schmidt FJ, et al. Gene organization and structure of the Streptomyces lividans gal operon. J Bacteriol. 1988; 170:203-212.
61. Croce CM, Tsujimoto Y, Erikson J, et al. Chromosome translocations and B cell neoplasia. Lab Invest. 1984;51:258-267.
62. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442.
63. Fiers W, Beyaert R, Declercq W, et al. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene. 1999;18: 7719-7730.
64. Shen H, Liu J, Wang Y, et al. Aflatoxin G-induced oxidative stress causes DNA damage and triggers apoptosis through MAPK signaling pathway in A549 cells. Food Chem Toxicol. 2013;62:661-669.
65. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994;35:950-954.
66. Terzic J, Grivennikov S, Karin E, et al. Inflammation and colon cancer. Gastroenterology. 2010;138:2101-2114 e5.
67. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
68. Gilson TP, Sollenberger LL. Adenocarcinoma of an ileostomy in a patient with familial adenomatous polyposis. Report of a case. Dis Colon Rectum. 1992;35:261-265.
69. Gillen CD, Walmsley RS, Prior P, et al. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590-1592.
70. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52:2015-2021.
71. Tsunada S, Iwakiri R, Ootani H, et al. Redox imbalance in the colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2003;38:1002-1003.
72. Kruidenier L, Kuiper I, Van Duijn W, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003;201:17-27.
73. Koch TR, Yuan LX, Stryker SJ, et al. Total antioxidant capacity of colon in patients with chronic ulcerative colitis. Dig Dis Sci. 2000;45:1814-1819.
74. Mueller S. Sensitive and nonenzymatic measurement of hydrogen peroxide in biological systems. Free Radic Biol Med. 2000;29:410-415.
75. Togashi H, Shinzawa H, Matsuo T, et al. Analysis of hepatic oxidative stress status by electron spin resonance spectroscopy and imaging. Free Radic Biol Med. 2000;28:846-853.
76. Faulkner K, Fridovich I. Luminol and lucigenin as detectors for O2. Free Radic Biol Med. 1993;15:447-451.
77. Kruidenier L, Kuiper I, Lamers CB, et al. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003;201:28-36.
78. Cao W, Vrees MD, Kirber MT, et al. Hydrogen peroxide contributes to motor dysfunction in ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2004;286:G833-G843.
79. Chiarpotto E, Scavazza A, Leonarduzzi G, et al. Oxidative damage and transforming growth factor beta 1 expression in pretumoral and tumoral lesions of human intestine. Free Radic Biol Med. 1997;22:889-894.
80. Holmes EW, Yong SL, Eiznhamer D, et al. Glutathione content of colonic mucosa: evidence for oxidative damage in active ulcerative colitis. Dig Dis Sci. 1998;43:1088-1095.
81. Szanto I, Rubbia-Brandt L, Kiss P, et al. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol. 2005;207:164-176.
82. Buffinton GD, Doe WF. Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radic Biol Med. 1995;19:911-918.
83. Spitz DR, Azzam EI, Li JJ, et al. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev. 2004;23:311-322.
84. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79-94.
85. Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Anl Rev Pharmacol Toxicol. 2003;43:233-260.
86. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. 2004;10: 549-557.
87. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci U S A. 2004;101:2040-2045.
88. McMahon M, Thomas N, Itoh K, et al. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redoxsensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem. 2004;279:31556-31567.
89. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284:13291-13295.
90. Winston JH, Li Q, Sarna SK. Paradoxical regulation of ChAT and nNOS expression in animal models of Crohn's colitis and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2013;305:G295-G302.
91. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76-86.
92. Kalthoff S, Ehmer U, Freiberg N, et al. Interaction between oxidative stress sensor Nrf2 and xenobiotic-activated aryl hydrocarbon receptor in the regulation of the human phase II detoxifying UDP glucuronosyltransferase 1A10. J Biol Chem. 2010;285:5993-6002.
93. Annese V, Bassotti G, Napolitano G, et al. Gastrointestinal motility disorders in patients with inactive Crohn's disease. Scand J Gastroenterol. 1997;32:1107-1117.
94. Snape WJ Jr, Williams R, Hyman PE. Defect in colonic smooth muscle contraction in patients with ulcerative colitis. Am J Physiol. 1991;261: G987-G991.
95. Vermillion DL, Huizinga JD, Riddell RH, et al. Altered small intestinal smooth muscle function in Crohn's disease. Gastroenterology. 1993; 104:1692-1699.
96. Vrees MD, Pricolo VE, Potenti FM, et al. Abnormal motility in patients with ulcerative colitis: the role of inflammatory cytokines. Arch Surg. 2002;137:439-445.
97. Mukhopadhyay S, Sekhar KR, Hale AB, et al. Loss of NRF2 impairs gastric nitrergic stimulation and function. Free Radic Biol Med. 2011;51: 619-625.
98. Ramakrishna BS, Varghese R, Jayakumar S, et al. Circulating antioxidants in ulcerative colitis and their relationship to disease severity and activity. J Gastroenterol Hepatol. 1997;12:490-494.
99. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev. 2009;61: 290-302.
100. Virgili F, Marino M. Regulation of cellular signals from nutritional molecules: a specific role for phytochemicals, beyond antioxidant activity. Free Radic Biol Med. 2008;45:1205-1216.
101. Surh YJ, Kundu JK, Na HK, et al. Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J Nutr. 2005;135:2993S-3001S.
102. Imlay JA. Pathways of oxidative damage. Annu Rev Microbiol. 2003;57: 395-418.
103. Vainshtein BK, Melik-Adamyan WR, Barynin VV, et al. Three-dimensional structure of the enzyme catalase. Nature. 1981;293:411-412.
104. Chelikani P, Fita I, Loewen PC. Diversity of structures and properties among catalases. Cell Mol Life Sci. 2004;61:192-208.
105. Yasmineh WG, Theologides A. Catalase as a roving scavenger of hydrogen peroxide: a hypothesis. J Lab Clin Med. 1993;122:110-114.
106. Giuffrida MA. Type II error and statistical power in reports of small animal clinical trials. J Am Vet Med Assoc. 2014;244:1075-1080.
107. Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. [published online ahead of print April 2, 2014]. doi:10.1111/opo.12131.
108. Chu FF, Esworthy RS, Chu PG, et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res. 2004;64:962-968.
109. Loguercio C, D'Argenio G, Delle Cave M, et al. Glutathione supplementation improves oxidative damage in experimental colitis. Dig Liver Dis. 2003;35:635-641.
110. M'Koma AE. Serum biochemical evaluation of patients with functional pouches ten to 20 years after restorative proctocolectomy. Int J Colorectal Dis. 2006;21:711-720.
111. M'Koma AE, Lindquist K, Liljeqvist L. Biochemical laboratory data in patients before and after restorative proctocolectomy. A study on 83 patients with a follow-up of 36 months. Ann Chir 1994;48:525-534.
112. M'Koma AE. Follow-up results of hematology data before and after restorative proctocolectomy. Clinical outcome. Dis Colon Rectum. 1994;37:932-937.
113. Nicholls RJ, Pezim ME. Restorative proctocolectomy with ileal reservoir for ulcerative colitis and familial adenomatous polyposis: a comparison of three reservoir designs. Br J Surg. 1985;72:470-474.
114. Christie PM, Hill GL. Return to normal body composition after ileoanal Jpouch anastomosis for ulcerative colitis. Dis Colon Rectum. 1990;33:584-586.
115. Geerling BJ, Badart-Smook A, Stockbrugger RW, et al. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr. 2000;54:514-521.
116. Esworthy RS, Aranda R, Martin MG, et al. Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol. 2001;281:G848-G855.
117. Forman HJ, Fridovich I. Superoxide dismutase: a comparison of rate constants. Arch Biochem Biophys. 1973;158:396-400.
118. Dincer Y, Erzin Y, Himmetoglu S, et al. Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci. 2007;52:1636-1641.
119. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
120. Pezim ME, Pemberton JH, Beart RW Jr, et al. Outcome of "indeterminant" colitis following ileal pouch-anal anastomosis. Dis Colon Rectum. 1989;32:653-658.
121. Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults. J Pediatr Gastroenterol Nutr. 2007;44:653-674.
122. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013;62:1505-1510.
123. Jones DT, Osterman MT, Bewtra M, et al. Passive smoking and inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103: 2382-2393.
124. Mikhailov TA, Furner SE. Breastfeeding and genetic factors in the etiology of inflammatory bowel disease in children. World J Gastroenterol. 2009;15:270-279.
125. Brandtzaeg P, Haraldsen G, Rugtveit J. Immunopathology of human inflammatory bowel disease. Springer Semin Immunopathol 1997;18: 555-589.
126. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46:336-343.
127. Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol. 1992;27: 609-614.
128. Gasparetto M, Guariso G. Highlights in IBD epidemiology and its natural history in the paediatric age. Gastroenterol Res Pract. 2013;2013: 829040.
129. Shikhare G, Kugathasan S. Inflammatory bowel disease in children: current trends. J Gastroenterol. 2010;45:673-682.
130. Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, et al. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. Inflamm Bowel Dis. 2013; 19:1218-1223.
131. Chouraki V, Savoye G, Dauchet L, et al. The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther. 2011;33:1133-1142.
132. Nosti PA, Stahl TJ, Sokol AI. Surgical repair of rectovaginal fistulas in patients with Crohn's disease. Eur J Obstet Gynecol Reprod Biol. 2013; 171:166-170.
133. Yheulon CG, Derosa DC, Gagliano RA. Retained pill camera at an entero-uracho-vesical fistula site in a patient with Crohn's disease. Hawaii J Med Public Health. 2013;72:186-189.
134. Nielsen OH, Rogler G, Hahnloser D, et al. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2009; 6:92-106.
135. Klineberg EO, James SP, Dunkin BJ. Crohn's disease complicated by a urachoenteric fistula. Dig Dis Sci. 2002;47:1728-1731.
136. Bergman R, Sloots CE. Diagnostic image (246). A man with faecal production of the umbilicus [in Dutch]. Ned Tijdschr Geneeskd. 2005; 149:1940.
137. Kavanagh DO, Carter MC, Keegan D, et al. Management of colorectal cancer in patients with inflammatory bowel disease. Tech Coloproctol. 2014;18:23-28.
138. Devroede GJ, Taylor WF, Sauer WG, et al. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med. 1971; 285:17-21.